Immediate placebo effect in Parkinson's disease - Is the subjective relief accompanied by objective improvement?

European Neurology

Volumn 56, Issue 4, 2006, Pages 222-229

  Fregni, Felipe ^a   Boggio, Paulo S ^b   Bermpohl, Felix ^a,c   Maia, Fernanda ^b   Rigonatti, Sergio P ^b   Barbosa, Egberto R ^b   Pascual Leone, Alvaro ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Levodopa; Parkinson's disease; Transcranial magnetic stimulation

Indexed keywords

LEVODOPA; PLACEBO;

ADULT; AGED; ARTICLE; BODY POSTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTION TEST; HUMAN; MALE; MOTOR PERFORMANCE; PARKINSON DISEASE; PILL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; TIME PERCEPTION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE; WALKING;

AGED; ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR SKILLS; PARKINSON DISEASE; PLACEBO EFFECT; PLACEBOS; REACTION TIME; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 33845594093     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096490     Document Type: Article

References (22)

1. Hrobjartsson A, Gotzsche PC: Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344:1594-1602.
2. Goetz CG, Leurgans S, Raman R, Stebbins GT: Objective changes in motor function during placebo treatment in PD. Neurology 2000;54:710-714.
3. Goetz CG, Leurgans S, Raman R: Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord 2002;17:283-288.
4. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ: Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001;293:1164-1166.
5. Strafella AP, Ko JH, Monchi O: Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation. Neuroimage, in press.
6. Vase L, Robinson ME, Verne GN, Price DD: Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain 2005;115:338-347.
7. Evans D: Suppression of the acute-phase response as a biological mechanism for the placebo effect. Med Hypotheses 2005;64:1-7.
8. Ruck A, Sylven C: 'Improvement' in the placebo group could be due to regression to the mean as well as to sociobiologic factors. Am J Cardiol 2006;97:152-153.
9. McDonald CJ, Mazzuca SA, McCabe GP Jr: How much of the placebo 'effect' is really statistical regression? Stat Med 1983;2:417-427.
10. Sturman MM, Vaillancourt DE, Metman LV, Bakay RA, Corcos DM: Effects of subthalamic nucleus stimulation and medication on resting and postural tremor in Parkinson's disease. Brain 2004;127:2131-2143.
11. Pascual-Leone A, Valls-Sole J, Brasil-Neto JP, Cohen LG, Hallett M: Akinesia in Parkinson's disease. I. Shortening of simple reaction time with focal, single-pulse transcranial magnetic stimulation. Neurology 1994;44:884-891.
12. Bornke C, Schulte T, Przuntek H, Muller T: Clinical effects of repetitive transcranial magnetic stimulation versus acute levodopa challenge in Parkinson's disease. J Neural Transm Suppl 2004;68:61-67.
13. Fregni F, Simon DK, Wu A, Pascual-Leone A: Non-invasive brain stimulation for Parkinson's disease: a systematic review and meta-analysis of the literature. J Neurol Neurosurg Psychiatry 2005;76:1614-1623.
14. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
15. Wassermann EM: Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol 1998;108:1-16.
16. Muller T, Benz S, Przuntek H: Choice reaction time after levodopa challenge in parkinsonian patients. J Neurol Sci 2000;181:98-103.
17. Spiro HM: Doctors, Patients, and Placebos. New Haven, Yale University Press, 1986.
18. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE: The importance of placebo effects in pain treatment and research. JAMA 1994;271:1609-1614.
19. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al: A doubleblind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.
20. Benedetti F, Pollo A, Lopiano L, Lanotte M, Vighetti S, Rainero I: Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 2003;23:4315-4323.
21. Allain H, Destee A, Petit H, Patay M, Schuck S, Bentue-Ferrer D, et al: Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group. Eur Neurol 2000;44:22-30.
22. Spiegel D, Kraemer H, Carlson RW: Is the placebo powerless? N Engl J Med 2001;345:1276.